<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180856</url>
  </required_header>
  <id_info>
    <org_study_id>RFPULM</org_study_id>
    <nct_id>NCT00180856</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation of Lung Tumors</brief_title>
  <official_title>A Phase II Study of Radiofrequency Ablation of Lung Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      Radiofrequency ablation has achieved impressive results in the treatment of unresectable&#xD;
      primary and metastatic liver cancer. Animal studies have demonstrated that radiofrequency can&#xD;
      fully ablate lung tumors in animal models. We set up a prospective study to evaluate the&#xD;
      local efficacy of radiofrequency ablation of lung neoplasms. The aim of the study is to&#xD;
      prospectively evaluate local efficacy with a minimal follow-up of one year, tolerance, lung&#xD;
      disease-free survival and survival after radiofrequency ablation of lung tumors (primary lung&#xD;
      cancer or lung metastases).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiofrequency (RF) ablation has achieved impressive results in the treatment of unresectable&#xD;
      primary and metastatic liver cancer. Animal studies have demonstrated that RF can fully&#xD;
      ablate lung tumors in animal models. We set up a prospective study to evaluate the local&#xD;
      efficacy of radiofrequency ablation of lung neoplasms with a minimal follow-up of one year.&#xD;
      The primary endpoint was to determine the rate of incomplete local treatment at 1 year. The&#xD;
      secondary endpoints were to evaluate tolerance, survival, disease-free survival and lung&#xD;
      tumor-free survival. Patients are followed-up by CT scan examination at day 1 or 2 before&#xD;
      discharge from the hospital, then at 2, 4, 6, 9 and 12 months and then at 2 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incomplete local treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung disease-free survival</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastasis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral or bilateral unresectable primary or metastatic lung tumors &lt;= 40 mm and a&#xD;
             number of tumor &lt;=5&#xD;
&#xD;
          -  Tumors located more than 1 cm from the hilum, and not involving soft tissues or&#xD;
             mediastinum.&#xD;
&#xD;
          -  Malignancy histologically proven for pulmonary nodules in patients with no history of&#xD;
             cancer outside the lung.&#xD;
&#xD;
          -  Lung tumors in patients with a known distant cancer history, has to be either&#xD;
             histologically proven or a demonstrated change in size of at least 25% in their&#xD;
             largest diameter is required on CT during the previous year&#xD;
&#xD;
          -  Pretreatment imaging work-up within 4 weeks of scheduled RF ablation (at least a chest&#xD;
             CT and an abdomino-pelvic CT)&#xD;
&#xD;
          -  If a tumor is found outside the lung, it has to be amenable to complete eradication&#xD;
             with RF or RF plus surgery&#xD;
&#xD;
          -  Lung spirometry within 4 weeks of treatment with a FEV1 &gt;= 1 liter&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncorrectable coagulopathy with a prothrombin time greater than 1.5 and a platelet&#xD;
             count below 106/mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry De Baere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Pallussière, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 11, 2005</last_update_submitted>
  <last_update_submitted_qc>September 11, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2005</last_update_posted>
  <keyword>Lung metastasis</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

